 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"DREAM Trial Final Results"Prof. Jonathan Shaw (biography)
English - 2006-09-15 - 51 minutes
|
 | (45 slides) |
Summary :
In this presentation Prof. Jonathan Shaw from the International Diabetes Institute in Melbourne, Australia gives a detailed account of the final results of the DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial presented yesterday at the 42nd EASD meeting in Copenhagen.
There has been growing evidence to suggest that in addition to lifestyle, metformin and acarbose, ACE inhibitors and thiazolidinediones may also prevent diabetes. The DREAM trial was designed to answer 2 questions: does ramipril 15 mg daily prevent diabetes, and does rosiglitazone 8 mg daily prevent diabetes? This was a double-blind, randomized clinical trial with a 2-by-2 factorial design, which randomly assigned 5269 participants without cardiovascular disease but with impaired fasting glucose or impaired glucose tolerance to receive ramipril or placebo and rosiglitazone or placebo, with a median follow-up of 3 years.
Overall, the DREAM trial showed that rosiglitazone has a substantial benefit on prevention of diabetes and regression to normoglycaemia, and ramipril has a modest benefit on regression to normoglycaemia. The durability of the glycaemic effect of these drugs is currently being assessed in a washout phase, and these findings are expected to be available this December.
Copyright © 2006 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
Final results from the ramipril and rosiglitazone arms of the DREAM trial:
- Primary outcome: Incident DM or death in individuals with IFG and/or IGT at baseline
- Regression to normal glucose levels
- Effects on blood pressure, liver function, weight, cardiovascular outcomes
- Adherence/adverse effects
Bibliographic references :
The DREAM Trial Investigators. Effect of Ramipril on the Incidence of Diabetes Published at www.nejm.org September 15, 2006 (10.1056/NEJMoa065061).
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. "Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial." The Lancet 2006; DOI:10.1016/S0140-6736(06)69420-8.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
